Directorate Change

Report this content

29 October 2020 07:00 GMT



Non-Executive Board Appointment

AstraZeneca PLC today announced that with effect from 1 November 2020, Diana Layfield is appointed as a Non-Executive Director.

Leif Johansson, Chairman of AstraZeneca, said: "We are delighted that Diana is joining AstraZeneca's Board. Her broad international business experience, which began in the pharmaceutical and biotech sector, encompasses leadership roles in international banking, global technology and a fintech start-up. Diana's expertise in delivering innovation at scale coupled with her passion for life sciences will be of great value to AstraZeneca as we continue to grow and invest for the future."

Diana Layfield is President, EMEA Partnerships at Google, driving technology transformation and solutions across all Google product areas for major partners in the region. She is also Vice-President, 'Next Billion Users' & Product Management, leading the development of products and services for future Google users, primarily in emerging markets. Prior to Google, Diana held senior positions at Standard Chartered Bank, including Chief Executive Officer, Africa Region; COO Wholesale Banking; and Group Head of Strategy & Corporate Development. Before joining Standard Chartered in 2004, she was Chief Executive Officer of a start-up technology company. Diana was previously a consultant at McKinsey & Co, becoming a sector lead for Healthcare and Life Sciences and advising pharmaceutical, biotech and other life sciences companies.


Diana has been a Non-Executive Director of Aggreko plc since 2012 and sits on the Board's Audit, Ethics and Corporate Responsibility, and Nomination Committees. She is a Council Member of the London School of Hygiene & Tropical Medicine.


Diana has a BA degree from the University of Oxford and an MA in Public Administration and International Economics from Harvard University.

Except as set out above, no disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZeneca.


For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit


Documents & Links